FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer
WALTHAM - ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the US Food and Drug Administration has filed the...